Closing in on the PumpKIN Trial of the Jarvik 2015 Ventricular Assist Device

J. Timothy Baldwin, Iki Adachi, John Teal, Christopher A. Almond, Robert D. Jaquiss, M. Patricia Massicotte, Kurt Dasse, Flora S. Siami, Victor Zak, Jonathan R. Kaltman, William T. Mahle, Robert Jarvik

Research output: Contribution to journalReview article

32 Citations (Scopus)

Abstract

The Infant Jarvik ventricular assist device (VAD; Jarvik Heart, Inc., New York, NY) has been developed to support the circulation of infants and children with advanced heart failure. The first version of the device was determined to have elevated hemolysis under certain conditions. The objective of this work was to determine appropriate modifications to the Infant Jarvik VAD that would result in acceptably low hemolysis levels. In vitro hemolysis testing revealed that hemolysis was related to the shape of the pump blade tips and a critical speed over which hemolysis would occur. Various design modifications were tested and a final design was selected that met the hemolysis performance goal. The new version was named the Jarvik 2015 VAD. Chronic in vivo tests, virtual fit studies, and a series of other performance tests were carried out to assess the device's performance characteristics. In vivo test results revealed acceptable hemolysis levels in a series of animals and virtual fit studies showed that the device would fit into children 8 kg and above, but could fit in smaller children as well. Additional FDA-required testing has been completed and all of the data are being submitted to the FDA so that a clinical trial of the Jarvik 2015 VAD can begin. Development of a Jarvik VAD for use in young children has been challenging for various reasons. However, with the hemolysis issue addressed in the Jarvik 2015 VAD, the device is well-poised for the start of the PumpKIN clinical trial in the near future.

Original languageEnglish (US)
Pages (from-to)9-15
Number of pages7
JournalSeminars in Thoracic and Cardiovascular Surgery: Pediatric Cardiac Surgery Annual
Volume20
DOIs
StatePublished - Jan 1 2017

Fingerprint

Heart-Assist Devices
Hemolysis
Equipment and Supplies
Clinical Trials
Heart Failure

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Surgery
  • Cardiology and Cardiovascular Medicine

Cite this

Closing in on the PumpKIN Trial of the Jarvik 2015 Ventricular Assist Device. / Baldwin, J. Timothy; Adachi, Iki; Teal, John; Almond, Christopher A.; Jaquiss, Robert D.; Massicotte, M. Patricia; Dasse, Kurt; Siami, Flora S.; Zak, Victor; Kaltman, Jonathan R.; Mahle, William T.; Jarvik, Robert.

In: Seminars in Thoracic and Cardiovascular Surgery: Pediatric Cardiac Surgery Annual, Vol. 20, 01.01.2017, p. 9-15.

Research output: Contribution to journalReview article

Baldwin, JT, Adachi, I, Teal, J, Almond, CA, Jaquiss, RD, Massicotte, MP, Dasse, K, Siami, FS, Zak, V, Kaltman, JR, Mahle, WT & Jarvik, R 2017, 'Closing in on the PumpKIN Trial of the Jarvik 2015 Ventricular Assist Device', Seminars in Thoracic and Cardiovascular Surgery: Pediatric Cardiac Surgery Annual, vol. 20, pp. 9-15. https://doi.org/10.1053/j.pcsu.2016.09.003
Baldwin, J. Timothy ; Adachi, Iki ; Teal, John ; Almond, Christopher A. ; Jaquiss, Robert D. ; Massicotte, M. Patricia ; Dasse, Kurt ; Siami, Flora S. ; Zak, Victor ; Kaltman, Jonathan R. ; Mahle, William T. ; Jarvik, Robert. / Closing in on the PumpKIN Trial of the Jarvik 2015 Ventricular Assist Device. In: Seminars in Thoracic and Cardiovascular Surgery: Pediatric Cardiac Surgery Annual. 2017 ; Vol. 20. pp. 9-15.
@article{15872c1e05a8400d944635231e37d9b9,
title = "Closing in on the PumpKIN Trial of the Jarvik 2015 Ventricular Assist Device",
abstract = "The Infant Jarvik ventricular assist device (VAD; Jarvik Heart, Inc., New York, NY) has been developed to support the circulation of infants and children with advanced heart failure. The first version of the device was determined to have elevated hemolysis under certain conditions. The objective of this work was to determine appropriate modifications to the Infant Jarvik VAD that would result in acceptably low hemolysis levels. In vitro hemolysis testing revealed that hemolysis was related to the shape of the pump blade tips and a critical speed over which hemolysis would occur. Various design modifications were tested and a final design was selected that met the hemolysis performance goal. The new version was named the Jarvik 2015 VAD. Chronic in vivo tests, virtual fit studies, and a series of other performance tests were carried out to assess the device's performance characteristics. In vivo test results revealed acceptable hemolysis levels in a series of animals and virtual fit studies showed that the device would fit into children 8 kg and above, but could fit in smaller children as well. Additional FDA-required testing has been completed and all of the data are being submitted to the FDA so that a clinical trial of the Jarvik 2015 VAD can begin. Development of a Jarvik VAD for use in young children has been challenging for various reasons. However, with the hemolysis issue addressed in the Jarvik 2015 VAD, the device is well-poised for the start of the PumpKIN clinical trial in the near future.",
author = "Baldwin, {J. Timothy} and Iki Adachi and John Teal and Almond, {Christopher A.} and Jaquiss, {Robert D.} and Massicotte, {M. Patricia} and Kurt Dasse and Siami, {Flora S.} and Victor Zak and Kaltman, {Jonathan R.} and Mahle, {William T.} and Robert Jarvik",
year = "2017",
month = "1",
day = "1",
doi = "10.1053/j.pcsu.2016.09.003",
language = "English (US)",
volume = "20",
pages = "9--15",
journal = "Pediatric Cardiac Surgery Annual",
issn = "1092-9126",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Closing in on the PumpKIN Trial of the Jarvik 2015 Ventricular Assist Device

AU - Baldwin, J. Timothy

AU - Adachi, Iki

AU - Teal, John

AU - Almond, Christopher A.

AU - Jaquiss, Robert D.

AU - Massicotte, M. Patricia

AU - Dasse, Kurt

AU - Siami, Flora S.

AU - Zak, Victor

AU - Kaltman, Jonathan R.

AU - Mahle, William T.

AU - Jarvik, Robert

PY - 2017/1/1

Y1 - 2017/1/1

N2 - The Infant Jarvik ventricular assist device (VAD; Jarvik Heart, Inc., New York, NY) has been developed to support the circulation of infants and children with advanced heart failure. The first version of the device was determined to have elevated hemolysis under certain conditions. The objective of this work was to determine appropriate modifications to the Infant Jarvik VAD that would result in acceptably low hemolysis levels. In vitro hemolysis testing revealed that hemolysis was related to the shape of the pump blade tips and a critical speed over which hemolysis would occur. Various design modifications were tested and a final design was selected that met the hemolysis performance goal. The new version was named the Jarvik 2015 VAD. Chronic in vivo tests, virtual fit studies, and a series of other performance tests were carried out to assess the device's performance characteristics. In vivo test results revealed acceptable hemolysis levels in a series of animals and virtual fit studies showed that the device would fit into children 8 kg and above, but could fit in smaller children as well. Additional FDA-required testing has been completed and all of the data are being submitted to the FDA so that a clinical trial of the Jarvik 2015 VAD can begin. Development of a Jarvik VAD for use in young children has been challenging for various reasons. However, with the hemolysis issue addressed in the Jarvik 2015 VAD, the device is well-poised for the start of the PumpKIN clinical trial in the near future.

AB - The Infant Jarvik ventricular assist device (VAD; Jarvik Heart, Inc., New York, NY) has been developed to support the circulation of infants and children with advanced heart failure. The first version of the device was determined to have elevated hemolysis under certain conditions. The objective of this work was to determine appropriate modifications to the Infant Jarvik VAD that would result in acceptably low hemolysis levels. In vitro hemolysis testing revealed that hemolysis was related to the shape of the pump blade tips and a critical speed over which hemolysis would occur. Various design modifications were tested and a final design was selected that met the hemolysis performance goal. The new version was named the Jarvik 2015 VAD. Chronic in vivo tests, virtual fit studies, and a series of other performance tests were carried out to assess the device's performance characteristics. In vivo test results revealed acceptable hemolysis levels in a series of animals and virtual fit studies showed that the device would fit into children 8 kg and above, but could fit in smaller children as well. Additional FDA-required testing has been completed and all of the data are being submitted to the FDA so that a clinical trial of the Jarvik 2015 VAD can begin. Development of a Jarvik VAD for use in young children has been challenging for various reasons. However, with the hemolysis issue addressed in the Jarvik 2015 VAD, the device is well-poised for the start of the PumpKIN clinical trial in the near future.

UR - http://www.scopus.com/inward/record.url?scp=85006459563&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006459563&partnerID=8YFLogxK

U2 - 10.1053/j.pcsu.2016.09.003

DO - 10.1053/j.pcsu.2016.09.003

M3 - Review article

VL - 20

SP - 9

EP - 15

JO - Pediatric Cardiac Surgery Annual

JF - Pediatric Cardiac Surgery Annual

SN - 1092-9126

ER -